Edwards Lifesciences/$EW
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Edwards Lifesciences
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
- Ticker
- $EW
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 16,000
- Headquarters
- Irvine, United States
- Website
- www.edwards.com
EW Metrics
BasicAdvanced
$58B
57.23
$1.76
0.83
-
Price and volume
Market cap
$58B
Beta
0.83
52-week high
$104.17
52-week low
$74.66
Average daily volume
4.3M
Financial strength
Current ratio
4.597
Quick ratio
3.541
Long term debt to equity
0.062
Total debt to equity
0.064
Interest coverage (TTM)
94.29%
Profitability
EBITDA (TTM)
2,094.7
Gross margin (TTM)
78.02%
Net profit margin (TTM)
15.30%
Operating margin (TTM)
28.82%
Effective tax rate (TTM)
31.05%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
8.77%
Return on equity (TTM)
9.33%
Valuation
Price to earnings (TTM)
57.231
Price to revenue (TTM)
8.732
Price to book
5.34
Price to tangible book (TTM)
7.49
Price to free cash flow (TTM)
40.929
Free cash flow yield (TTM)
2.44%
Free cash flow per share (TTM)
2.463
Growth
Revenue change (TTM)
13.44%
Earnings per share change (TTM)
-24.39%
3-year revenue growth (CAGR)
9.44%
10-year revenue growth (CAGR)
8.82%
3-year earnings per share growth (CAGR)
-9.10%
10-year earnings per share growth (CAGR)
7.65%
What the Analysts think about EW
Analyst ratings (Buy, Hold, Sell) for Edwards Lifesciences stock.
Analyst projections of the future price of Edwards Lifesciences stock.
Bulls say / Bears say
Second-quarter sales rose 13.6% and Edwards raised its 2026 sales-growth outlook to 10%–11%, signalling stronger demand across its portfolio than it had expected. It kept its adjusted earnings outlook unchanged. (Edwards Lifesciences)
In the PROGRESS trial, TAVR cut the two-year risk of death or heart-failure events by 33% versus clinical surveillance in moderate aortic stenosis patients with risk features. If the results support a future label expansion, they could widen the market, although this use remains investigational. (Edwards Lifesciences)
The FDA approved Edwards’ PASCAL system for tricuspid repair, and the CLASP II TR trial found better clinical and quality-of-life outcomes than medical therapy alone. These results and the new US indication give its mitral and tricuspid therapies a route to reach more patients. (Edwards Lifesciences, Edwards Lifesciences)
The FDA flagged certain Commander M delivery-system lots used with SAPIEN M3 after reports of balloon bursts linked to one death and one serious injury. The alert and product withdrawal could weigh on confidence in this newer mitral-valve offering. (Fierce Biotech)
Edwards said second-quarter TAVR growth benefited from a competitor’s market exit a year earlier, and described that benefit in Europe as nearing its end. As that favourable comparison fades, the core business may find it harder to sustain recent growth rates. (Edwards Lifesciences)
Foreign exchange reduced second-quarter adjusted gross margin by about 70 basis points, and management expected the 2026 margin to land near the low end of its range. Tariff exposure adds another source of cost uncertainty that could limit earnings growth. (Yahoo Finance)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2026.
EW Financial Performance
Revenues and expenses
EW Earnings Performance
Company profitability
Upcoming events
No upcoming events
EW News
AllArticlesVideos
Edwards Lifesciences Highlights PASCAL, TAVR Data Showing Patient Benefits
MarketBeat3 days ago
CLASP II TR Trial Demonstrates Superior Clinical, Quality-of-Life Benefits With Edwards PASCAL System
Business Wire4 days ago
Progress Trial Demonstrates Edwards TAVR Is Superior to Clinical Surveillance for Moderate AS Patients With At-Risk Features
Business Wire4 days ago
Funds containing EW
AllUSDEURGBP
Fund name | Fund size | $EW weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 1.29% |
iShares Healthcare Innovation€2B78 | $1.2B | 1.29% |
iShares MSCI World Health Care Sector Advanced€CBUF | $683M | 1.29% |
iShares MSCI World Health Care Sector Advanced£WHCA | $362M | 1.29% |
iShares Healthcare Innovation$HEAL | $1.3B | 1.29% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.